Both in Pharmaceuticals
Ocular Therapeutix vs uniQure
Over the past year OCUL returned −40.2% and QURE returned −30.4%; their daily moves had a correlation of 0.01.
OCUL −40.2% QURE −30.4%Growth of $1, one year, split-adjusted
| Metric | OCUL | QURE |
|---|---|---|
| Price | $6.82 | $23.87 |
| Market cap | $1.50B | $1.66B |
| Today | +1.34% | +3.92% |
| 1 month | −5.9% | +4.7% |
| 6 months | −29.8% | +12.8% |
| Year to date | −43.8% | −0.3% |
| 1 year | −41.5% | −64.7% |
| Revenue growth (YoY) | +0.1% | +11.0% |
| Gross margin | 85.1% | 94.0% |
| Net margin | −584.5% | −1387.8% |
| P/E (TTM) | — | — |
| Price / sales | 28.8× | 88.7× |
| Net cash | $525.8M | $760.2M |
| Dividend yield | — | — |
| Volatility (60d) | 75.6% | 109.1% |
| Short % of float | 15.1% | 13.2% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).